Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-HER2 TAC T cells TAC01-HER2

A preparation of autologous T lymphocytes that are genetically engineered with a T-cell Antigen Coupler (TAC), comprising of a domain that targets the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2) and another domain that binds to the endogenous T-cell receptor (TCR), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-HER2 TAC T cells TAC01-HER2 targets and binds to HER2-expressing tumor cells and activates TCR-mediated signaling pathways, leading to T-cell-mediated killing of HER2-expressing tumor cells. HER-2, a tyrosine kinase receptor for epidermal growth factor (EGF) (also known as neu and ErbB2), is overexpressed by a variety of cancers.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-HER2 T-cell antigen coupler-expressing T cells TAC01-HER2
TAC-engineered T cells TAC01-HER2
Code name:TAC 01-HER2
TAC-01-HER2
TAC01-HER2
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search